Overview

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).
Phase:
Phase 3
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
Empagliflozin